RESEARCH Open Access

Herbal adaptogens combined with protein fractions from bovine colostrum and hen egg yolk reduce liver TNF-α expression and protein carbonylation in Western diet feeding in rat

Advanced Burner Test Reactor Preconceptual Design Report.

The goals of the Global Nuclear Energy Partnership (GNEP) are to expand the use of nuclear energy to meet increasing global energy demand, to address nuclear waste management concerns and to promote non-proliferation. Implementation of the GNEP requires development and demonstration of three major technologies: (1) Light water reactor (LWR) spent fuel separations technologies that will recover transuranics to be recycled for fuel but not separate plutonium from other transuranics, thereby providing proliferation-resistance; (2) Advanced Burner Reactors (ABRs) based on a fast spectrum that transmute the recycled transuranics to produce energy while also reducing the long term radiotoxicity and decay heat loading in the repository; and (3) Fast reactor fuel recycling technologies to recover and refabricate the transuranics for repeated recycling in the fast reactor system. The primary mission of the ABR Program is to demonstrate the transmutation of transuranics recovered from the LWR spent fuel, and hence the benefits of the fuel cycle closure to nuclear waste management. The transmutation, or burning of the transuranics is accomplished by fissioning and this is most effectively done in a fast spectrum. In the thermal spectrum of commercial LWRs, some transuranics capture neutrons and become even heavier transuranics rather than being fissioned. Even with repeated recycling, only about 30% can be transmuted, which is an intrinsic limitation of all thermal spectrum reactors. Only in a fast spectrum can all transuranics be effectively fissioned to eliminate their long-term radiotoxicity and decay heat. The Advanced Burner Test Reactor (ABTR) is the first step in demonstrating the transmutation technologies. It directly supports development of a prototype full-scale Advanced Burner Reactor, which would be followed by commercial deployment of ABRs. The primary objectives of the ABTR are: (1) To demonstrate reactor-based transmutation of transuranics as part of an advanced fuel cycle; (2) To qualify the transuranics-containing fuels and advanced structural materials needed for a full-scale ABR; and (3) To support the research, development and demonstration required for certification of an ABR standard design by the U.S. Nuclear Regulatory Commission. The ABTR should also address the following additional objectives: (1) To incorporate and demonstrate innovative design concepts and features that may lead to significant improvements in cost, safety, efficiency, reliability, or other favorable characteristics that could promote public acceptance and future private sector investment in ABRs; (2) To demonstrate improved technologies for safeguards and security; and (3) To support development of the U.S. infrastructure for design, fabrication and construction, testing and deployment of systems, structures and components for the ABRs. Based on these objectives, a pre-conceptual design of a 250 MWt ABTR has been developed; it is documented in this report. In addition to meeting the primary and additional objectives listed above, the lessons learned from fast reactor programs in the U.S. and worldwide and the operating experience of more than a dozen fast reactors around the world, in particular the Experimental Breeder Reactor-II have been incorporated into the design of the ABTR to the extent possible

The relationship between the degree of thrombocytopenia and infection with Ehrlichia canis in an endemic area

Ehrlichia canis is the causative agent of canine monocytic ehrlichiosis. In order to evaluate platelet counts as a screening test for E. canis in an endemic area, 217 whole blood samples from dogs were divided into three groups: 71 non-thrombocytopenic samples (group A, platelet counts greater than 200000/muL) and 146 thrombocytopenic samples (less than 200000/muL). The thrombocytopenic group was further divided into 62 with platelet counts between 100000-200000/muL (Group B) and 84 samples with less than 100000 platelets/muL (Group C). All samples were examined for the presence of a segment of the Ehrlichia canis 16S rRNA gene using a nested polymerase chain reaction. Sixty-seven of the 217 samples (30.9%) were positive for the presence of the E. canis 16S rRNA gene; 53 (63.1%) of the group C samples and 13 (21%) of group B. Only one (1.4%) of the non-thrombocytopenic samples (Group A) was positive. These data support the concept that platelet counts may be a good screening test for canine monocytic ehrlichiosis, and that the magnitude of thrombocytopenia may increase the reliability of diagnosis